Investor Presentaiton

Best change in sum of diameters from baseline, % 80 60 40 20 20 Dato-DXd Encouraging Combination Data in 1L NSCLC TROPION-Lung02 study (ASCO 2023) Dato-DXd + Pembrolizumab (Doublet) and additional platinum chemotherapy (Triplet) demonstrated encouraging antitumor activity All patients (n=124)a Doublet Triplet ORR 38% [26-51]d ORR 49% [37-61]d 80 60 40 20 1L patients only (n=84)a Doublet Triplet ORR 50% [32-68]d ORR 57% [42-70]d 0 ++ otokollok lok slok Holotok Molok ****ololok ok ok ** **** *ok olololololololololok ok okolokolok * *olok > + +++ +++++ 가아아아아아 아아아ok жok Daiichi-Sankyo ****** ***** ** ****** ******* ** * * ******* ***** ***: **** ** 0 ********* + +++ ++ + -20 ++++ + + + ++ ++ + ++ -40 ++++ +++ + + + -60 ++++ +++ + -20 -40 -60 Doublet Triplet + Treatment ongoing * Dato-DXd 6 mg/kg b + + +++ +++. +++++++++++ + *** *** ** -80 -100 -80 -100 The left graph includes the patients with NSCLC in the 1L and 2L+ settings Data cutoff: April 7, 2023 The most common adverse events of Dato-DXd in this study were stomatitis, nausea, anemia, fatigue which were comparable to the known profile of Dato-DXd ■ Observed stomatitis and ILD/pneumonitis as AESI, predominantly grade 1 or 2 (no grade 4 or 5 ILD/pneumonitis observed) a Patients with no baseline target lesions or no postbaseline tumor assessments were excluded from the waterfall plots. b Planned dose level. © Responses pending confirmation. d 95% confidence interval 1L: first line, AESI: adverse events of special interest, ASCO: American Society of Clinical Oncology, Cl: confidence interval, ILD: interstitial lung disease, NSCLC: non small cell lung cancer, ORR: objective response rate, TEAE: treatment 21 emergent adverse events

View entire presentation